While HAART has significantly impacted the AIDS epidemic it will not end the epidemic;the need is to purge the body of infection which will require the use of drugs that reach into bone marrow, brain, any tissue that harbors latent HIV and clear or lower these viral reservoirs to make HAART unnecessary. Animal models were not required for design of antiretroviral drugs, but are an essential preclinical step to test the ability of drugs to induce latent HIV and eradicate latent viral reservoirs. Because of potential toxicity and unknown efficacy of such drugs, an effective animal model is critical for testing of therapeutic agents that will induce/eradicate latent HIV for design of clinical trials. We have a rigorous SIV model of HAART in HIVinfected individuals that reduces viral load in peripheral blood and cerebrospinal fluid (CSF) to undetectable levels and have latent virus in CD4+ T cells and macrophages in tissues, brain and spleen. HIV eradication requires HAART that includes CNS-penetrant antiretrovirals (ARTs) since brain is a site of viral latency. We will optimize a CNS-penetrant HAART regimen using current ART drugs using our SIV macaque, confirming that drugs reach effective levels in tissues quantitating CSF and brain levels of each antiretroviral drug. Using this SIV HAART model, the hypothesis that latent viral reservoirs (in addition to CD4+ T cells) in cells ofthe monocyte/macrophage lineage and potentially in CD34+ cells exist, and that an animal model is required to identify, quantitate and characterize these reservoirs. We hypothesize that viral infection can be eradicated from tissues by inducing virus reactivation from latently infected cells and preventing completion ofthe virus life cycle by ART that effectively penetrate tissues, including brain. We will characterize latent reservoirs in this SIV model in CD4+ T cells, monocytes, tissue macrophages and OD34+ cells (brain, spleen, bone marrow, lymph nodes, lung and gut). We will test induction/eradication drugs in SIV-infected macaques with HAART once the number of latently infected resting CD4+ T cells plateaus in plasma, quantitate residual virus replication and latently infected cells in plasma, CSF and spleen biopsies before and after induction therapy. We will examine the time to virus reactivation after withdrawal from HAART and successful induction/eradication therapy may result in no virus reactivation. We will use such a successful treatment regimen to dissect the molecular basis ofthis induction/eradication approach.

Public Health Relevance

HAART has impacted the HIV epidemic. Although these drugs are highly effective, latency of HIV in CD4+ T cells and cells in tissues currently requires life long HAART. Thus, novel therapy is needed to eradicate or reduce viral latency in HIV-infected individuals so that HAART can be discontinued without the reactivation of latent virus. Animal models are crucial for the development of such therapy since to rigorously test induction eradication therapy the individual or animal must be withdrawn from HAART and virus allowed to reactivate.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Honeycutt, Jenna B; Sheridan, Patricia A; Matsushima, Glenn K et al. (2015) Humanized mouse models for HIV-1 infection of the CNS. J Neurovirol 21:301-9
Manson McManamy, Mary E; Hakre, Shweta; Verdin, Eric M et al. (2014) Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother 23:145-9
King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5
Spivak, Adam M; Andrade, Adriana; Eisele, Evelyn et al. (2014) A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 58:883-90
Duverger, Alexandra; Wolschendorf, Frank; Anderson, Joshua C et al. (2014) Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol 88:364-76
Denton, Paul W; Long, Julie M; Wietgrefe, Stephen W et al. (2014) Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog 10:e1003872
Abreu, Celina M; Price, Sarah L; Shirk, Erin N et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9:e97257
Archin, Nancie M; Margolis, David M (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27:29-35
Liu, Pingyang; Xiang, Yanhui; Fujinaga, Koh et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289:9918-25
Persaud, Deborah; Patel, Kunjal; Karalius, Brad et al. (2014) Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr 168:1138-46

Showing the most recent 10 out of 77 publications